via The Scientist RSS https://ift.tt/WhVxrYm Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial. https://ift.tt/ciej9Ll September 26, 2022 at 08:36PM